Management of hepatorenal syndrome in patients with cirrhosis

Nature Reviews Nephrology

Volumn 7, Issue 9, 2011, Pages 517-526

  Arroyo, Vicente ^a   Fernández, Javier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOGLYCOSIDE; CEFALOTIN; CIPROFLOXACIN; DIURETIC AGENT; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OCTREOTIDE; PENTOXIFYLLINE; PLACEBO; SULFAMETHOXAZOLE; TERLIPRESSIN; TRIMETHOPRIM; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ACUTE HEPATITIS; ADRENERGIC SYSTEM; ALBUMIN DIALYSIS; ALCOHOL LIVER DISEASE; ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BRAIN DISEASE; DEHYDRATION; FLUID RETENTION; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; HYPOVOLEMIA; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE NECROSIS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NEPHROTOXICITY; PARACENTESIS; PATHOGENESIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VASOCONSTRICTION; VASOPRESSIN BLOOD LEVEL;

EDUCATION, MEDICAL, CONTINUING; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 80052272944     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.96     Document Type: Review

References (110)

1. Epstein, M. et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am. J. Med. 49, 175-185 (1970).
2. Epstein, M., Schneider, N. & Befeler, B. Relationship of systemic and intrarenal hemodynamics in cirrhosis. J. Lab. Clin. Med. 89, 1175-1187 (1977). (Pubitemid 8130190)
3. Henriksen, J. H., Ring-Larsen, H. & Christensen, N. J. Catecholamines in plasma from artery, cubital vein, and femoral vein in patients with cirrhosis. Significance of sampling site. Scand. J. Clin. Lab. Invest. 46, 39-44 (1986). (Pubitemid 16105273)
4. Henriksen, J. H. et al. Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 16, 1163-1170 (1992).
5. Arroyo, V., Fernandez, J. & Ginès, P. Pathogenesis and treatment of hepatorenal syndrome. Semin. Liver Dis. 28, 81-95 (2008). (Pubitemid 351326535)
6. Arroyo, V. & Colmenero, J. Ascites and hepatorenal syndrome in cirrhosis: Pathophysiological basis of therapy and current management. J. Hepatol. 38 (Suppl. 1), S69-S89 (2003).
7. Maroto, A. et al. Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. Hepatology 17, 788-793 (1993). (Pubitemid 23150086)
8. Sacerdoti, D. et al. Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: Relationships with portal hemodynamics. Gastroenterology 108, 1152-1158 (1995).
9. Iversen, P. et al. Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy. Gastroenterology 136, 863-871 (2009).
10. Ruiz-del-Arbol, L. et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38, 1210-1218 (2003). (Pubitemid 37314829)
11. Ruiz-del-Arbol, L. et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42, 439-447 (2005).
12. Krag, A., Bendtsen, F., Henriksen, J. H. & Møller, S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 59, 105-110 (2010).
13. Hecker, R. & Sherlock, S. Electrolyte and circulatory changes in terminal liver failure. Lancet 271, 1121-1125 (1956).
14. Koppel, M. H. et al. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N. Engl. J. Med. 280, 1367-1371 (1969).
15. Guevara, M. et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27, 35-41 (1998). (Pubitemid 28041531)
16. Hadengue, A. et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J. Hepatol. 29, 565-570 (1998). (Pubitemid 28484945)
17. Le Moine, O. et al. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastroenterol. Belg. 61, 268-270 (1998). (Pubitemid 28280643)
18. Angeli, P. et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29, 1690-1697 (1999). (Pubitemid 29247040)
19. Gülberg, V., Bilzer, M. & Gerbes, A. L. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30, 870-875 (1999). (Pubitemid 29458273)
20. Uriz, J. et al. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J. Hepatol. 33, 43-48 (2000). (Pubitemid 30418933)
21. Alessandria, C. et al. Renal failure in cirrhotic patients: Role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur. J. Gastroenterol. Hepatol. 14, 1363-1368 (2002). (Pubitemid 36054926)
22. Duvoux, C. et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 36, 374-380 (2002). (Pubitemid 34810356)
23. Halimi, C. et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: Results of a multicentre pilot study. Eur. J. Gastroenterol. Hepatol. 14, 153-158 (2002). (Pubitemid 34163994)
24. Moreau, R. et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 122, 923-930 (2002). (Pubitemid 34267275)
25. Ortega, R. et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 36, 941-948 (2002).
26. Alessandria, C. et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study. J. Hepatol. 47, 499-505 (2007). (Pubitemid 47331744)
27. Neri, S. et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig. Dis. Sci. 53, 830-835 (2008). (Pubitemid 351317073)
28. Martín-Llahí, M. et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study. Gastroenterology 134, 1352-1359 (2008). (Pubitemid 351626950)
29. Sanyal, A. J. et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134, 1360-1368 (2008). (Pubitemid 351615358)
30. Gonwa, T. A., Morris, C. A., Goldstein, R. M., Husberg, B. S. & Klintmalm, G. B. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 51, 428-430 (1991).
31. Gonwa, T. A. et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: Where will MELD lead us? Am. J. Transplant. 6, 2651-2659 (2006). (Pubitemid 44571685)
32. Nair, S., Verma, S. & Thuluvath, P. J. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 35, 1179-1185 (2002). (Pubitemid 34454015)
33. Restuccia, T. et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J. Hepatol. 40, 140-146 (2004). (Pubitemid 38064723)
34. Arroyo, V., Terra, C. & Ginès, P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J. Hepatol. 46, 935-946 (2007). (Pubitemid 46529046)
35. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol. 53, 397-417 (2010).
36. Salerno, F., Gerbes, A., Ginès, P., Wong, F. & Arroyo, V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56, 1310-1318 (2007). (Pubitemid 47300435)
37. Arroyo, V. et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23, 164-176 (1996). (Pubitemid 26012105)
38. Follo, A. et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 20, 1495-1501 (1994). (Pubitemid 24359062)
39. Toledo, C. et al. Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 17, 251-257 (1993). (Pubitemid 23046697)
40. Terra, C. et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: Value of MELD score. Gastroenterology 129, 1944-1953 (2005). (Pubitemid 41772972)
41. Fasolato, S. et al. Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features. Hepatology 45, 223-229 (2007). (Pubitemid 46144382)
42. Francés, R. et al. Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. Clin. Exp. Immunol. 150, 230-237 (2007). (Pubitemid 47609571)
43. Francés, R. et al. Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis. J. Clin. Immunol. 27, 438-444 (2007). (Pubitemid 46906658)
44. Such, J., Muñoz, C., Zapater, P. & Pérez-Mateo, M. Bacterial DNA induces a proinflammatory immune response in patients with decompensated cirrhosis. Gut 54, 1500 (2005). (Pubitemid 41375210)
45. Such, J. et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 36, 135-141 (2002). (Pubitemid 34700770)
46. Boyer, T. D., Zia, P. & Reynolds, T. B. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 77, 215-222 (1979). (Pubitemid 9206030)
47. Zipser, R. D., Hoefs, J. C., Speckart, P. F., Zia, P. K. & Horton, R. Prostaglandins: Modulators of renal function and pressor resistance in chronic liver disease. J. Clin. Endocrinol. Metab. 48, 895-900 (1979).
48. Epstein, M., Lifschitz, M., Ramachandran, M. & Rappaport, K. Characterization of renal prostaglandin E responsiveness in decompensated cirrhosis: Implications for renal sodium handling. Clin. Sci. (Lond.) 63, 555-563 (1982). (Pubitemid 13213947)
49. Zipser, R. D., Radvan, G. H., Kronborg, I. J., Duke, R. & Little, T. E. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: Evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 84, 697-703 (1983). (Pubitemid 13152614)
50. Pérez-Ayuso, R. M. et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int. 26, 72-80 (1984). (Pubitemid 14060591)
51. Laffi, G., La Villa, G., Pinzani, M., Marra, F. & Gentilini, P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin. Nephrol. 17, 530-548 (1997). (Pubitemid 27465011)
52. Cabrera, J. et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 82, 97-105 (1982). (Pubitemid 12183309)
53. Garcia-Tsao, G., Parikh, C. R. & Viola, A. Acute kidney injury in cirrhosis. Hepatology 48, 2064-2077 (2008).
54. Guevara, M. et al. Effects of contrast media on renal function in patients with cirrhosis: A prospective study. Hepatology 40, 646-651 (2004). (Pubitemid 39265586)
55. Cárdenas, A. et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 34, 671-676 (2001). (Pubitemid 32927990)
56. Ginés, P. et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 93, 234-241 (1987). (Pubitemid 17097585)
57. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol. 53, 397-417 (2010).
58. Moore, K. P. et al. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology 38, 258-266 (2003). (Pubitemid 36775818)
59. Shear, L., Ching, S. & Gabuzda, G. J. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N. Engl. J. Med. 282, 1391-1396 (1970).
60. Sugano, S. Endotoxin levels in cirrhotic rats with sterile and infected ascites. Gastroenterol. Jpn 27, 348-353 (1992).
61. Heller, J. et al. Effects of lipopolysaccharide on TNF-alpha production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J. Hepatol. 33, 376-381 (2000). (Pubitemid 30663374)
62. Navasa, M. et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality. Hepatology 27, 1227-1232 (1998). (Pubitemid 28227848)
63. Sort, P. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. 341, 403-409 (1999). (Pubitemid 29362513)
64. Crawford, D. H. et al. Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am. J. Kidney Dis. 19, 339-344 (1992).
65. Axelsen, R. A. et al. Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation. Pathology 27, 237-246 (1995).
66. Trawalé, J. M. et al. The spectrum of renal lesions in patients with cirrhosis: A clinicopathological study. Liver Int. 30, 725-732 (2010).
67. Malyszko, J. Biomarkers of acute kidney injury in different clinical settings: A time to change the paradigm? Kidney Blood Press. Res. 33, 368-382 (2010).
68. Duseja, A. et al. Non-hepatic insults are common acute precipitants in patients with acute on chronic liver failure (ACLF). Dig. Dis. Sci. 55, 3188-3192 (2010).
69. Novelli, G. et al. Predictive parameters after molecular absorbent recirculating system treatment integrated with model for end stage liver disease model in patients with acute-on-chronic liver failure. Transplant. Proc. 42, 1182-1187 (2010).
70. Wasmuth, H. E. et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J. Hepatol. 42, 195-201 (2005). (Pubitemid 40143465)
71. Xing, T., Li, L., Cao, H. & Huang, J. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin. Exp. Immunol. 147, 184-188 (2007). (Pubitemid 44915570)
72. Escorsell Mañosa, A. & Mas Ordeig, A. Acute on chronic liver failure [Spanish]. Gastroenterol. Hepatol. 33, 126-134 (2010).
73. Ring-Larsen, H., Hesse, B., Henriksen, J. H. & Christensen, N. J. Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: Plasma norepinephrine concentration, hepatic extraction, and renal release. Hepatology 2, 304-310 (1982). (Pubitemid 12011897)
74. Ring-Larsen, H. Renal blood flow in cirrhosis: Relation to systemic and portal haemodynamics and liver function. Scand. J. Clin. Lab. Invest. 37, 635-642 (1977). (Pubitemid 8387492)
75. Schrier, R. W. et al. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8, 1151-1157 (1988).
76. Reichenbach, V., Ros, J. & Jiménez, W. Endogenous cannabinoids in liver disease: Many darts for a single target [Spanish]. Gastroenterol. Hepatol. 33, 323-329 (2010).
77. Genesca, J. et al. Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: Relationship to nitric oxide. Dig. Dis. Sci. 44, 372-376 (1999). (Pubitemid 29093563)
78. Iwakiri, Y. & Groszmann, R. J. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. Hepatology 43 (2 Suppl. 1), S121-S131 (2006).
79. Sieber, C. C., Lopez-Talavera, J. C. & Groszmann, R. J. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 104, 1750-1754 (1993). (Pubitemid 23235468)
80. Sikuler, E. & Groszmann, R. J. Hemodynamic studies in long- and short-term portal hypertensive rats: The relation to systemic glucagon levels. Hepatology 6, 414-418 (1986). (Pubitemid 16086629)
81. De las Heras, D. et al. Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology 38, 452-459 (2003). (Pubitemid 36919867)
82. Arroyo, V., Ginés, P., Rimola, A. & Gaya, J. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am. J. Med. 81, 104-122 (1986). (Pubitemid 16006987)
83. Fernández-Varo, G. et al. Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am. J. Pathol. 162, 1985-1993 (2003). (Pubitemid 36613055)
84. Claria, J. et al. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 100, 494-501 (1991).
85. Daskalopoulos, G., Pinzani, M., Murray, N., Hirschberg, R. & Zipser, R. D. Effects of captopril on renal function in patients with cirrhosis and ascites. J. Hepatol. 4, 330-336 (1987). (Pubitemid 17080471)
86. Colmenero, J. et al. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G726-G734 (2009).
87. Ginès, P. et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94, 1493-1502 (1988).
88. Ginès, A. et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111, 1002-1010 (1996). (Pubitemid 26327603)
89. Runyon, B. A. & AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: An update. Hepatology 49, 2087-2107 (2009).
90. Colle, I. et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis. J. Gastroenterol. Hepatol. 17, 882-888 (2002).
91. Solanki, P. et al. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J. Gastroenterol. Hepatol. 18, 152-156 (2003). (Pubitemid 36349860)
92. Gluud, L. L., Christensen, K., Christensen, E. & Krag, A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 51, 576-584 (2010).
93. Nazar, A. et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 51, 219-226 (2010).
94. Angeli, P. et al. Terlipressin given as continuous intravenous infusion versus terlipressin given as intravenous boluses in the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis [abstract 175]. J. Hepatol. 50 (Suppl. 1), S73 (2009).
95. Sharma, P., Kumar, A., Shrama, B. C. & Sarin, S. K. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am. J. Gastroenterol. 103, 1689-1697 (2008).
96. Wong, F., Pantea, L. & Sniderman, K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40, 55-64 (2004). (Pubitemid 38868923)
97. Esrailian, E., Pantangco, E. R., Kyulo, N. L., Hu, K. Q. & Runyon, B. A. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig. Dis. Sci. 52, 742-748 (2007).
98. Skagen, C., Einstein, M., Lucey, M. R. & Said, A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J. Clin. Gastroenterol. 43, 680-685 (2009).
99. Guevara, M. et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 28, 416-422 (1998). (Pubitemid 28363668)
100. Brensing, K. A. et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: A phase II study. Gut 47, 288-295 (2000). (Pubitemid 30489776)
101. Testino, G. et al. Type-2 hepatorenal syndrome and refractory ascites: Role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 50, 1753-1755 (2003). (Pubitemid 37467926)
102. Keller, F. et al. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): The role of hemodialysis. Ren. Fail. 17, 135-146 (1995).
103. Capling, R. K. & Bastani, B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren. Fail. 26, 563-568 (2004). (Pubitemid 39363289)
104. Hassanein, T. I. et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46, 1853-1862 (2007).
105. Rifai, K. et al. Extracorporeal liver support by fractionated plasma separation and adsorption (Prometheus) in patients with acute-on-chronic liver failure (Helios study): A prospective randomized controlled multicenter study [abstract 6]. J. Hepatol. 52 (Suppl. 1), S3 (2010).
106. Bañares, R. et al. Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF trial [abstract 1184]. J. Hepatol. 52 (Suppl. 1), S459-S460 (2010).
107. Henriksen, J. H., Kiszka-Kanowitz, M. & Bendtsen, F. Review article: Volume expansion in patients with cirrhosis. Aliment. Pharmacol. Ther. 16 (Suppl. 5), 12-23 (2002). (Pubitemid 41759558)
108. Fernández, J. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133, 818-824 (2007). (Pubitemid 47374144)
109. Terg, R. et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study. J. Hepatol. 48, 774-779 (2008).
110. Akriviadis, E. et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 119, 1637-1648 (2000). (Pubitemid 32198689)